Seoul, Korea – December 23, 2025 – (SeaPRwire) – The Third Market Co., Ltd. has opened Korea’s first Experiential Refurbished Electronics Showroom, a space where customers can directly test, compare, and verify refurbished electronics with full transparency. The showroom was created to solve long-standing consumer concerns around inconsistent quality and unclear product history in the refurb market. The Third Market manages the entire process in-house, including inspection, grading, labeling, and warranty issuance. Visitors can observe real-time inspection, review visualized product reports, and experience devices firsthand—shifting refurbished products from “low-cost alternatives” to “value-verified choices.” The showroom integrates an inspection center, exhibition zone, and logistics area, enabling seamless processing from intake to purchase. With its internal branding and design team, Third Market provides standardized labels, branded packaging, and expert consultations to enhance consumer trust. A dedicated Small Business Pop-Up Zone also supports local merchants by offering a new retail channel for overstock and returned goods, contributing to a healthier refurb ecosystem. “Our goal is to establish a new standard of trust in refurbished electronics,” said CEO Sang-ho Yoo. “Customers should be able to see exactly how products are evaluated and feel confident in their value.” The Third Market plans to expand additional hubs, enhance automated inspection technology, and strengthen global partnerships as it shapes the future of the refurbished electronics market. Media contact Brand: The Third Market Contact: Sang-ho Yoo Phone: +821041143582 Email: biz@ttm.imWebsite: https://shop.ttm.im
王睿億總監以科技為善【芯善同行】傳遞教育與公益新力量
在科技日新月異的時代，創新不只是改變生活的工具，更承載社會責任，拉近人與人之間的距離。長期深耕自動化、智慧製造與綠能領域的王睿億總監，始終相信企業的價值不僅來自技術實力，更源於對社會的關懷與承擔。 多年來，王總監帶領團隊持續投入教育、環境保護及弱勢關懷，讓企業在成長的同時，也能為社會注入溫暖力量。他強調：「科技若缺乏人性，就會失去方向；企業若沒有溫度，就難以長久。」 「芯善同行」理念落地 推動「芯光陪伴計畫」 秉持「芯善同行」的核心精神，公司啟動「芯光陪伴計畫」，聚焦偏鄉及資源有限的學習環境。計畫透過改善資訊設備、導入數位學習資源及科技體驗課程，陪伴孩子接觸科技、培養創造力，讓學習不再受地域限制。 王睿億總監表示：「我們希望用科技作為陪伴的起點，讓孩子在學習路上不孤單，也能看見更多可能。」 讓公益成為日常的一部分 除了對外公益投入，王總監也從企業內部出發，鼓勵同仁親身參與志工服務，投入課後陪伴、社區關懷與環境行動，讓善意不只停留在理念，而是化為實際行動。 他認為，公益不是少數人的付出，而是可以被更多人參與、共同完成的過程。透過營造支持公益參與的企業文化，讓每位員工在工作之外也能實踐回饋社會。 【芯善同行】善心回饋 愛心待用餐啟動此次愛心待用餐活動，是因總監在半導體工作上取得階段性成果，將部分收益回饋給員工與社會。他常說：「取之於社會，用之於社會。」 這份回饋不僅是一份感謝，更是一份責任與善念的延續。希望透過善舉傳遞溫暖，讓更多人感受到支持與陪伴。 · 發放時間：12/20起 發放地點：阿興滷肉飯－ 台灣新北市中和區南山路238-1號 王睿億總監表示：「這次的善意不是唯一一次，也不是最後一次。未來【芯善同行】將持續推動更多善舉，幫助社會上每個需要協助的角落。」 以科技為橋 連結更好的未來 展望未來，王睿億總監將持續深化「芯善同行」的實踐，推動「芯光陪伴計畫」，串聯企業、教育單位與在地社群，為社會累積更多正向影響力。 他表示，當科技與善意並肩前行，不僅能改變產業，更能照亮人心，為下一代播下希望的種子。 芯善同行，讓科技成為陪伴的力量， 在每一個需要的角落持續發光。 共同打造一個更公平、更具永續精神的社會。 他說：「當科技與善意同行，世界就會變得更溫暖」。讓科技不只是進步的工具，而是傳遞希望的光。
Asia Pricing Professionals Launches Major 2026 Expansion with Global Certification Partnership and Two Flagship Conferences in Singapore
Singapore – December 22, 2025 – (SeaPRwire) – Asia Pricing Professionals (APP), the leading pricing and commercial excellence community in Asia-Pacific, today announced a major expansion of its professional development, certification, and community platform for 2026. The expanded portfolio positions APP as the region’s most comprehensive ecosystem for pricing, value management, and revenue excellence. Central to the 2026 expansion is a strategic partnership with the Professional Pricing Society (PPS), connecting global best practices with regional execution to support individuals, teams, and organizations as pricing evolves into a strategic, AI-enabled business capability. Comprehensive Pricing Training & Global Certifications From 2026, APP members will gain access to 100+ on-demand pricing courses through its collaboration with PPS, covering the full pricing and monetization lifecycle — from foundational principles to advanced real-world application. The curriculum spans: Pricing strategy and value creation Pricing analytics and data-driven decision-making Execution, governance, and price realization Negotiation and deal pricing SaaS and XaaS monetization models AI-enabled pricing and advanced analytics Organizational design and change management In addition, APP will offer globally recognized certifications, including the Certified Pricing Professional (CPP®) designation — the only worldwide credential synthesizing the art and science of pricing — and a new AI Pricing Certification, designed to help professionals apply artificial intelligence responsibly and effectively in pricing, forecasting, and commercial decision-making. Two Flagship APP Conferences in Singapore (2026) As part of its expanded offering, APP will host two one-day flagship conferences in Singapore in 2026, bringing together senior pricing, commercial, and revenue leaders from across Asia-Pacific. APP Conference 1 5 March 2026 | Singapore Theme: Smart Value: AI and the Future of Pricing & Revenue Growth The conference will explore how AI, analytics, and advanced pricing capabilities are transforming value creation, pricing decisions, and sustainable revenue growth. Key topics include AI-driven pricing, predictive analytics, price corridors, deal pricing, execution excellence, and ethics and governance in AI-enabled pricing. APP Conference 2 15 October 2026 | Singapore Theme: Total Revenue Excellence: Integrating Pricing, Profitability & Commercial Performance This event will focus on breaking organizational silos between Pricing, Sales, Finance, Revenue Management, and Commercial Operations to drive end-to-end revenue and profit performance. Key topics include deal desk design, discount discipline, KPI alignment, commercial operating models, and scaling revenue excellence across regions. Face-to-Face Training & Regional Networking Immediately following each conference, APP will deliver in-person, instructor-led training programs in Singapore on 6 March and 16 October 2026. These hands-on sessions focus on applied execution and advanced case work, and both count toward CPP® certification credits. In the second half of 2026, APP will also launch its “Five Big Cities” Networking Tour, with events planned in: Bangkok Jakarta Manila Shanghai Singapore Each event will feature curated networking, practitioner roundtables, and thought leadership discussions, strengthening APP’s role as a regional connector between local markets and global best practices. An Integrated Pricing Ecosystem for Asia-Pacific Together, APP’s training, certifications, conferences, live programs, and regional networking form a single integrated ecosystem designed to: Build pricing and commercial capability at scale Bridge theory with real-world execution Support career progression and organizational maturity Advance ethical, data-driven, and AI-enabled pricing across Asia-Pacific About Asia Pricing Professionals (APP) Founded in 2010, Asia Pricing Professionals is a not-for-profit community dedicated to advancing pricing, value management, and commercial excellence across Asia-Pacific. APP connects practitioners, leaders, and organizations through education, certification, events, and peer collaboration. Social Links LinkedIn: https://www.linkedin.com/groups/3813123/ Instagram: https://www.instagram.com/asiapricingprofessionals Media contact Brand: Asia Pricing Professionals Contact: Media team Email: deepaksood@asiapricingprofessionals.org Website: https://asiapricingprofessionals.org
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
SHENZHEN, Dec 15, 2025 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing. In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile[1]. In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future. Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo. The Product’s inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options. The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries). About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib 2. Datas are from the China Insights Consultancy (CIC) report CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/
Global Leadership Redefined: Andy Lin, Violist and Erhu Virtuoso, Unveils Vision for International Arts Academy in Asia
Dec. 11, 2025 - (SeaPRwire) - According to a report published by "The Icons", highly accomplished violist and Erhu Virtuoso Andy Lin successfully redefined the traditional image of leadership during his tenure as President of the World Taiwanese Chambers of Commerce – Junior Chapter (WTCCJC). By leveraging his unique blend of cultural artistry and human warmth, Lin injected a dynamic new spirit and connectivity into the international organization, and has now announced his next major endeavor: establishing a pioneering international academy of performing arts in Asia. Unlike previous WTCCJC presidents, who often came from established corporate backgrounds, Lin, a musician with a Doctor of Musical Arts degree, chose a distinctly different path. He emphasized that his approach was not dictated by titles or authority, but by treating every member with "artistic sensitivity and human warmth." Lin described his leadership style as akin to performing "chamber music," promoting coordination and collective decision-making over command and control, stating that true harmony arises from finding balance among diverse voices rather than relying on the loudest voice. Throughout his presidency, Lin traveled tirelessly across six continents, attending over thirty conferences and community events. Through impromptu musical performances and genuine one-on-one dialogue, he transformed WTCCJC into a comprehensive platform for cross-cultural exchange. Lin noted that this dedication to human connection and cultural engagement yielded the most fulfilling results, effectively turning a traditionally rule-bound organization into a bridge for shared vision and trust across continents. A significant outcome of his tenure was the creation and performance of "The Song of WTCCJC." This original composition quickly became a powerful, unifying symbol for the organization, with its opening line, "When stars gather from every corner of the world," serving as an emotional anchor for global members. Lin stressed that culture is a form of governance that unites people through shared emotions and symbols, making cross-continental collaboration effortless and leading to tangible results, such as connecting premium Vietnamese coffee to the New York market and supporting a Japanese medical-aesthetics brand's entry into the U.S. healthcare system. Following his successful term, Lin has shifted his focus to a new, major cultural initiative: establishing a world-class performing arts academy in Taiwan. This institution is planned to transcend conventional boundaries, integrating music, theatre, dance, interdisciplinary creation, and cultural technology. Lin's vision is to nurture creativity and cultural dialogue, making the academy a destination for global artists and effectively positioning Asia as a future center for the performing arts. He firmly believes that the school will become a meeting point for young artists from every nation, who will become "carriers of culture, taking Taiwan's stories back to the world—and bringing the world's colors into Taiwan." This culture-driven leadership model is set to continue its profound influence on the next generation of global leaders.
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
SHENZHEN, Dec 11, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke. With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms. Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals. The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients. More Information about Y-3 for Injection The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects. The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability. On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent. About Stroke According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001. 2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/
CryptoFeeDiscount Launches Free Crypto Trading Fee Calculator for Binance, OKX, Bitget, and 25+ Global Exchanges
New York, NY – December 08, 2025 – (SeaPRwire) – CryptoFeeDiscount, a premier cryptocurrency data aggregation platform, today announced the official launch of its advanced Crypto Trading Fee Savings Calculator. Designed for quant institutions and high-volume traders, this new data-driven engine reveals hidden transaction costs and identifies optimized execution strategies to reduce trading fees by up to 30%. As crypto market volatility increases in late 2025, transaction costs have become a silent profit killer for active traders. A typical futures trader generating $5 to $10 million in monthly volume can lose upwards of $400 to $600 per month in unnecessary maker/taker fees without optimized account structuring. CryptoFeeDiscount addresses this issue by providing a transparent, data-driven interface that allows users to: Compare Real-Time Rates: Instantly visualize the cost difference between top-tier derivatives exchanges like Bitget and Binance. Unlock VIP Fee Discounts for Free: Access exclusive, institutional-grade fee reductions usually reserved for VIP 1-3 levels, bypassing standard trading volume requirements. Verify Promo Codes: Utilize the platform’s database of verified Referral Codes and Promo Codes to ensure maximum sign-up bonuses and lifetime fee rebates. Discover Niche Opportunities: Filter exchanges by specific criteria, such as “Privacy-First” features for secure trading or high-leverage trading options. “Most retail traders obsess over entry and exit prices but completely ignore the frictional cost of trading,” said James Anderson, Lead Analyst at CryptoFeeDiscount. “Our data shows that by simply switching execution venues or applying a verified discount code on platforms like Bitget, a scalper can increase their net profitability by over 15% annually. We built this calculator to make that math visible and actionable.” The platform has already verified and indexed active promo codes for major platforms, ensuring users have access to the lowest possible rates currently available on the market, with savings reaching up to 30% on select crypto exchanges. ABOUT CRYPTOFEEDISCOUNT CryptoFeeDiscount is a leading financial technology website dedicated to transparency in cryptocurrency trading costs. Through its proprietary comparison engine and rigorous verification process, the platform helps traders find the best execution venues, referral codes, and sign-up bonuses. MEDIA CONTACT Brand: CryptoFeeDiscount Contact: James Anderson Email: team@CryptoFeeDiscount.com Website: https://CryptoFeeDiscount.com
Leapfrog Acquisition Corp Announces Pricing of $125,000,000 Initial Public Offering
SUMMIT, N.J. – December 05, 2025 – (SeaPRwire) – Leapfrog Acquisition Corporation (the “Company”) announced today the pricing of its initial public offering of 12,500,000 units at a price of $10.00 per unit. The units are expected to commence trading on December 5, 2025 on the Global Market tier of The Nasdaq Stock Market LLC under the symbol LFACU. The Company, which is led by Matthew R. Pollard, Abhay N. Pande and Kevin M. Murphy, is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Each unit sold in the offering consists of one Class A ordinary share (an “ordinary share”) and one half of one redeemable warrant with a strike price of $11.50 per ordinary share exercisable within 5 years of the Company completing an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and warrants are expected to be listed on the Global Market tier of The Nasdaq Stock Market LLC under the symbols “LFAC” and “LFACW,” respectively. BTIG, LLC is serving as the sole book-running manager of the offering. The underwriters have been granted a 45-day option to purchase up to an additional 1,875,000 units at the initial public offering price to cover over-allotments, if any. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on December 4, 2025. The offering was made only by means of a prospectus, copies of which, when available, may be obtained by contacting BTIG, LLC, 65 East 55 Street, New York, NY 10022, by emailing ProspectusDelivery@btig.com, or by visiting the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Leapfrog Acquisition Corp Leapfrog Acquisition Corp is a blank check company organized for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or engaging in any other similar business combination with one or more businesses or entities. The Company is led by Chief Executive Officer, Matthew R. Pollard, President and Chief Investment Officer, Abhay N. Pande and Chief Financial Officer, Kevin M. Murphy. The Company will prioritize businesses in the international energy supply chain and critical minerals sectors, including their related infrastructure in its search for attractive merger candidates. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the anticipated use of the proceeds of the Company’s initial public offering, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements, including those set forth in the risk factors section of the registration statement and prospectus for the Company’s initial public offering. Copies of these documents can be accessed through the SEC’s website at www.sec.gov. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law. Media Contact Company: Leapfrog Acquisition Corp Contact: Media Team Telephone: +1-201-379-4200 LinkedIn: https://www.linkedin.com/company/leapfrog-acquisition-corporation Email In the US: abhay@leapfrogspac.com Email In Asia: matt@leapfrogspac.com kevin@leapfrogspac.com
Polytek Engineering 成為 ORCA 在香港的獨家經銷及服務合作夥伴
Hong Kong - 2025年12月01日 - (SeaPRwire) - 全球領先的現場食物垃圾消化技術公司 ORCA 宣佈，與保得工程有限公司（Polytek Engineering Co. Ltd.）建立合作關係，成為其在香港的獨家經銷商及服務夥伴。此項合作標誌著 ORCA 在香港持續擴張的重要一步，並支持其在大灣區及東南亞市場的更廣泛佈局。 應對香港的食物垃圾挑戰 香港在廢物管理方面持續面臨重大挑戰。2023 年，全港每天棄置的都市固體廢物（MSW）平均達 10,884 公噸。食物垃圾依然是最大單一廢物流，占比 29%，即每日約 3,191 公噸(info.gov.hk)。 政府已取得顯著進展——2023 年家庭食物垃圾棄置量下降 12.6%，回收率則由前一年的 32% 上升至 33% (info.gov.hk)。 然而，商業及工業部門每天仍產生近 1,000 公噸的食物垃圾，突顯需要具規模性、可持續的解決方案，以配合現有措施，並支持香港的長遠減廢目標 (epd.gov.hk)。 推動可持續發展的合作關係 ORCA 食物垃圾消化機提供現場處理方案，將食物垃圾轉化為環保的排放水，減少運輸排放、保護堆填區容量，並協助企業達成可持續發展指標。 保得工程是專業廚房、洗衣房及冷庫系統的可靠領導者，擁有數十年設計、供應、安裝及售後服務經驗。他們在專案設計及構思階段的角色，使其能夠在新建或翻新專案中無縫整合 ORCA 技術，確保從一開始便納入食物垃圾減量方案。 關於 ORCA ORCA 是現場食物垃圾消化技術的先驅，提供的系統可幫助企業減少對堆填區及運輸的依賴、降低溫室氣體排放，並最終從源頭減少食物垃圾。 “這項合作是解決香港迫切食物垃圾問題的重要一步。”ORCA CEO Louis Anagnostakos 表示，“雖然 ORCA 仍將繼續作為獨立的全球公司運營，但通過將我們的創新技術與保得的工程專長結合，我們能夠加速可持續解決方案在商業領域及大灣區的應用。” 關於保得工程有限公司 保得工程有限公司是香港、澳門及中國內地領先的專業廚房、洗衣房及冷庫解決方案供應商，業務涵蓋設計、供應、安裝及長期服務，為客戶提供高性能、量身定制的方案。 “保得一直致力於提供高性能、面向未來的廚房及設施方案。”保得工程總經理曾志添（Joseph Tsang）表示，“通過此次獨家合作，我們能夠在專案最早的設計階段引入 ORCA， 經過驗證的食物垃圾技術，讓客戶從一開始便將可持續性融入其營運之中。”
Polytek Engineering Selected as ORCA’s Exclusive Distributor and Service Partner for Hong Kong
Hong Kong – December 01, 2025 – (SeaPRwire) – ORCA, a global leader in on-site food-waste digestion technology, has partnered with Polytek Engineering Co. Ltd. as its exclusive distributor and service partner for Hong Kong. This collaboration marks an important step in ORCA’s continued expansion in Hong Kong and contributes to its wider presence throughout the Greater Bay Area and Southeast Asia markets. Addressing Hong Kong’s Food Waste Challenge Hong Kong continues to face significant challenges in waste management. In 2023, the city disposed of an average of 10,884 tonnes of municipal solids waste (MSW) per day. Food waste remained the largest single component, accounting for 29% or about 3,191 tonnes daily (info.gov.hk). The government has made commendable progress—household food waste disposal fell by 12.6%, and recovery rates increased to 33% in 2023, up from 32% the previous year (info.gov.hk). Still, the commercial and industrial sector contributes close to 1,000 tonnes of food waste daily, underscoring the need for scalable, sustainable solutions that can complement existing initiatives and support Hong Kong’s long-term waste reduction goals (epd.gov.hk). A Partnership for Sustainable Impact ORCA Digesters provide on-site solutions that convert food waste into environmentally safe water, reducing transportation emissions, protecting landfill capacity, and helping businesses meet sustainability targets. Polytek Engineering is a trusted leader in professional kitchen, laundry, and cold storage systems, with decades of expertise in design, supply, installation, and after-sales service. Their role at the design and conception phase of projects uniquely positions them to integrate ORCA technology into new builds and retrofits, ensuring food waste diversion is considered from the outset. About ORCA ORCA is a pioneer in on-site food waste digestion technology, offering systems that help businesses reduce landfill and transportation reliance, cut greenhouse gas emissions and ultimately reduce food waste at the source. “This partnership marks an important step toward addressing Hong Kong’s pressing food-waste challenge,” said Louis Anagnostakos — CEO, ORCA. “While ORCA continues to operate as an independent global company, by integrating our innovative technology with Polytek’s engineering expertise we can accelerate adoption of sustainable solutions across the commercial sector and the wider Greater Bay Area.” About Polytek Engineering Co. Ltd Polytek Engineering Co. Ltd is a leading provider of professional kitchen, laundry, and cold storage solutions in Hong Kong, Macau, and Mainland China. With expertise across design, supply, installation, and long-term service, Polytek delivers high-performance solutions tailored to client needs. “Polytek has always focused on delivering high-performance, future-ready kitchen and facility solutions,” said Joseph Tsang — General Manager, Polytek. “Through this exclusive partnership, we can now bring ORCA’s proven food waste technology into projects at the earliest design stage—helping our clients build sustainability directly into their operations from inception.”
Kyrgyzstan launches $50M gold-backed USDKG stablecoin to modernize cross-border payments
Bishkek, Kyrgyz Republic – November 29, 2025 – (SeaPRwire) – Kyrgyzstan has officially launched USDKG, a gold-backed stablecoin pegged 1:1 to the U.S. dollar, with an initial issue of $50 million. The token is issued on Tron and fully audited by ConsenSys Diligence, with future expansion slated to include Ethereum support. The issuer, OJSC Virtual Asset Issuer, is a state-owned entity under the Ministry of Finance, operating within the legal framework established by the 2022 Law on Virtual Assets of the Kyrgyz Republic. The initiative represents a first-of-its-kind model in Central Asia, merging sovereign oversight with blockchain transparency. The launch ceremony was attended by Sadyr Japarov, President of the Kyrgyz Republic, Almaz Baketaev, Minister of Finance, and Biibolot Mamytov, CEO of Gold Dollar, the project’s operator. During the event, the dignitaries pressed a symbolic “Launch Issuance” button, officially initiating the circulation of USDKG tokens. The issuance of USDKG is carried out by a company with 100% state participation, ensuring a high level of investor trust and institutional reliability. A total of 50,000,000 USDKG tokens have been issued, each fully backed by physical gold reserves. Operational control — including gold management — is delegated to a private company registered in the Kyrgyz Republic, under a contractual agreement with the USDKG issuer. This separation of responsibilities ensures independent operational oversight and positions USDKG outside the classification of a Central Bank Digital Currency (CBDC). The company responsible for managing USDKG’s gold reserves, has outlined plans to expand the backing to $500 million in the next phase, with a long-term target of $2 billion. The stablecoin is fully compliant with FATF KYC/AML standards, and redemptions require standard identity verification. It is designed to facilitate financial inclusion. Kyrgyzstan is among the first nations in the region to establish a comprehensive digital-asset regulatory framework, setting a precedent for state-supervised virtual currencies. Government representatives emphasized that such initiatives aim to enhance economic transparency and trade efficiency, rather than serve any geopolitical agenda. Officials also noted that USDKG complements, rather than competes with, the national monetary system. The project reframes traditional narratives around state-issued and commodity-backed digital assets. Its gold collateral serves as a verifiable, inflation-resistant foundation, aligning with a growing market preference for transparent, real-asset-backed stablecoins. By combining physical reserves with on-chain verification, USDKG introduces a model of measurable stability uncommon in the current stablecoin landscape. The state-backed structure provides a clear regulatory framework built on accountability and public oversight. The Kyrgyz initiative underscores a broader trend toward responsible digital-asset innovation in emerging markets. The government’s focus on regulatory discipline, transparency, and tangible reserves signals a pragmatic approach to blockchain-based modernization. With USDKG, Kyrgyzstan positions itself as a regional first-mover in regulated asset-backed digital currencies — both bridging traditional finance and blockchain infrastructure and maintaining full sovereign oversight. Media contact Brand: Kyrgyzstan Contact: Media team Email: business@usdkg.com Website: https://www.usdkg.com
三百萬玩家加入 dEmpire of Vampire：BNB Chain 上的暗黑幻想掀起P2E熱潮
移動遊戲遇上區塊鏈：這款動作 RPG 證明玩家真正渴望的是既好玩又能真正擁有遊戲資產的體驗 Dubai, UAE - 2025年11月28日 - (SeaPRwire) - 當 Vameon 推出 dEmpire of Vampire 的 beta 測試版本時，團隊只有一個簡單的信念：**只要你做出真正優秀的遊戲，玩家自然會來。**如今，隨著下載量突破 300 萬次，這一信念得到了充分驗證。這款基於 BNB Smart Chain 的暗黑幻想動作 RPG 正在證明：遊戲的未來無需在“樂趣”與“玩家所有權”之間做選擇，而是兩者兼得。Vameon 的 dEmpire of Vampire 目前在 Google Play 和 Appstore 都是熱門遊戲。 “我們看到區塊鏈遊戲行業一直在被一個根本性問題困擾，”Borax 說，“太多專案從加密概念開始，卻忘了做一個玩家真正想玩的遊戲。我們徹底反其道而行之。” 最終呈現的是一款首先在品質上媲美頂級移動 RPG 的遊戲，玩家甚至稱其為“移動端遇到過最龐大的 3D 地圖”——仿佛倫敦地下通道與地牢的沉浸式探索體驗。 至於區塊鏈元素？它們被自然地融入遊戲，允許玩家真正擁有角色、裝備與成就，並作為可交易數位資產進行流通。 建一個真正可持續的經濟體系 更有趣的部分在這裡。團隊並沒有簡單地在遊戲中加一個 Token 就稱其為 “play-to-earn”。他們花了大量時間研究這些經濟模型為何會崩盤：通脹、不可持續的獎池、玩家把遊戲當提款機。 他們的解決方案？ VON Token 採用基於表現的獎勵機制——獎勵方式看你“怎麼玩”，而不只是“有玩”。 你的收益取決於： 戰鬥技術 對遊戲的投入程度 與社區的互動 獎勵由團隊稱為 “Power x ORA” 的公式計算，衡量你在戰鬥中的統治力與整體活躍度。 但更巧妙的是其周邊機制：只有達到 Premium 玩家 才能進入主獎勵池，創造了真正的稀缺性。未領取的獎勵在 30 天后徹底銷毀。整體經濟模型強調長期穩定，而非短期炒作。 “我們不是想讓每個人一夜暴富，”Borax 說，“我們要打造的是一個 五年後仍然運行的系統。” 也許最出人意料的創新，是 Vameon 所說的 “Free-to-Play Resurrection”（免費復活）：玩家死亡？看 15 秒廣告即可復活。 簡單，卻同時解決兩點問題： 免費玩家不會卡在付費牆外 遊戲獲得穩定收入支持長期開發 這是那種讓你忍不住問：“為什麼別的遊戲都沒想到？”的創意。 言語成武器：最新更新內容 最新發佈的 “Words Have Power” 更新為遊戲帶來全新體驗。玩家現在可以在戰鬥中開口說出技能片語來改變戰局。這並非噱頭，而是加入了需要時機、判斷的策略層次。 此次更新也將角色成長體系擴展到裝備升級，讓構築玩法更加多樣。在 Labyrinth 場景新增了 2v2 與 3v3 戰鬥模式，且加入環境陷阱，隨時可能逆轉勝負。遊戲現在支援 13 種語言，真正面向全球玩家群體。 不只是一款遊戲 Vameon 的野心不僅限於 dEmpire of Vampire。 VON Token 將作為整個遊戲生態的通用貨幣，未來新作將共用同一經濟體系。現在的玩家所累積的資產，都將在未來作品中繼續發揮價值。 團隊還計畫推出： Staking Tournaments（質押錦標賽），玩家可競爭 USDT 獎金 Global Championship（全球錦標賽），打造專屬電競生態 這對遊戲行業意味著什麼 300 萬次 beta 下載本身意義重大，但更重要的是這些數字背後反映的趨勢： 玩家正在渴望一種真正尊重玩家時間、努力與資產所有權的遊戲體驗——同時又能保持高品質與強可玩性。 dEmpire of Vampire 並非完美——沒有遊戲是完美的。但它正在提出區塊鏈遊戲領域最重要的問題：當開發者真正把“遊戲好玩”放在首位時，區塊鏈遊戲應當是什麼樣？ 該遊戲現已在 iOS 與 Android 上線，並將在全年保持持續更新。 About Vameon Vameon 致力於打造他們自己也想玩的遊戲：高品質體驗，同時讓玩家真正擁有自己的數字資產。他們的旗艦作品 dEmpire of Vampire，將動作 RPG 的玩法與 BNB Smart Chain 上的數字資產所有權完美結合。 Media Contact Email: info@vameon.com Website: https://vameon.com Telegram: https://t.me/vameon